- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
AREDS2 study to test home monitoring
The National Eye Institute (NEI) has launched an ancillary study to the ongoing Age-Related Eye Disease Study 2, which has the aim of determining whether oral supplementation of lutein/zeaxanthin and omega-3 fatty acids can further slow the progression of vision loss from age-related macular degeneration.
St. Louis-The National Eye Institute (NEI) has launched an ancillary study to the ongoing Age-Related Eye Disease Study 2 (AREDS2), which has the aim of determining whether oral supplementation of lutein/zeaxanthin and omega-3 fatty acids can further slow the progression of vision loss from age-related macular degeneration (AMD).
The objective of the ancillary study is to determine whether home monitoring using a proprietary monitor (ForeseeHome AMD Monitor, Notal Vision) will lead to earlier detection of wet AMD when compared with standard care and will result in better visual acuity following therapy at 1 year.
The proprietary monitor is the first ophthalmic device designed to provide ongoing monitoring of patients with AMD between visits to an eye-care professional. Patients complete a brief exam on the monitor in their own homes, and data are transmitted to the company’s monitoring center.
